Affimed NV
NASDAQ:AFMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jeil Pharma Holdings Inc
KRX:002620
|
KR |
|
J
|
Jiangsu Hengshang Energy Conservation Technology Co Ltd
SSE:603137
|
CN |
Affimed NV
Total Receivables
Affimed NV
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Affimed NV
NASDAQ:AFMD
|
Total Receivables
€4.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
31%
|
CAGR 10-Years
16%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Receivables
€984.9m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Total Receivables
€22.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Receivables
€6.9m
|
CAGR 3-Years
49%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Receivables
€196.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
0%
|
|
|
Formycon AG
XETRA:FYB
|
Total Receivables
€30.8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
44%
|
CAGR 10-Years
25%
|
|
Affimed NV
Glance View
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
See Also
What is Affimed NV's Total Receivables?
Total Receivables
4.5m
EUR
Based on the financial report for Sep 30, 2024, Affimed NV's Total Receivables amounts to 4.5m EUR.
What is Affimed NV's Total Receivables growth rate?
Total Receivables CAGR 10Y
16%
Over the last year, the Total Receivables growth was 86%. The average annual Total Receivables growth rates for Affimed NV have been 7% over the past three years , 31% over the past five years , and 16% over the past ten years .
